Exercise for the mitigation of cancer therapy-related cardiac dysfunction in breast cancer patients treated with anthracyclines: a systematic review and meta-analysis.
Alejandro Jiménez Marín, María Virginia García-Coll, Evelyn Martín Moraleda et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis evaluated the impact of long-term exercise on cancer therapy-related cardiac dysfunction (CTRCD) in breast cancer patients treated with anthracyclines. Analyzing six randomized controlled trials with 360 participants, the study found that exercise significantly reduced cardiac troponin I elevation compared to usual care (SMD = -0.50; p = 0.02), indicating a potential cardioprotective effect.
Key findings
- Exercise significantly reduced cardiac troponin I elevation compared to controls (SMD = -0.50; p = 0.02).
- No significant differences were found for left ventricular ejection fraction or global longitudinal strain.
- The analysis included six randomized controlled trials with a total of 360 participants.
- Further investigation is needed to confirm the cardioprotective role of exercise.
Why it matters
Understanding the potential cardioprotective effects of exercise during anthracycline treatment is crucial for managing the cardiovascular health of breast cancer patients, particularly as CTRCD can significantly impact long-term outcomes.